pf-03654764
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2009 (NCT00989391)
Timeline
Indications
Mechanism of action
- Histamine H3 receptorANTAGONIST
HRH3 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)CNC(=O)[C@H]1C[C@@](F)(c2ccc(CN3CCCC3)c(F)c2)C1- Mol. weight
- 350.45 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2206292 ↗
Also known as
- 3-fluoro-3-(3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl)-n-(2-methylpropyl)cyclobutanecarboxamide
- pf03654764
- pf 03654764
- pf-03654764
- pf-03654764
- pf-03654764
- pf-03654764
- pf-03654764
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01298505 | Phase 1 | Jun 1, 2010 | Pfizer |
| NCT01033396 | Phase 2 | Jan 1, 2010 | Pfizer |
| NCT00989391 | Phase 1 | Oct 1, 2009 | Pfizer |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 3 | 3 | 2 | 2009 |
1 organizations
Page 1 / 1